Pro Medicus Limited Q2 Results
Pro Medicus Limited Q2 Results Leading health imaging company Pro Medicus Limited (ASX: PME) reported a strong financial performance for the first half of the 2024 fiscal year, posting a net profit of $51.7 million, a 42.7% increase compared to…
Superior HealthPlan Named Best Place for Working Parents® in Texas
Superior HealthPlan Named Best Place for Working Parents® in Texas Superior HealthPlan, a prominent managed care organization in Texas and a subsidiary of Centene Corporation (NYSE: CNC), has been named a Best Place for Working Parents® for the fifth consecutive…
Cigna Foundation Accepting 2025 Youth Mental Health Grant Applications
Cigna Foundation Accepting 2025 Youth Mental Health Grant Applications The Cigna Group Foundation, the philanthropic branch of The Cigna Group (NYSE: CI), is stepping up efforts to address the growing mental health crisis among young people. As part of a…
QIAGEN Expands Bioinformatics Leadership with New Data Center in Asia-Pacific
QIAGEN Expands Bioinformatics Leadership with New Data Center in Asia-Pacific QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has officially opened a new data center in Melbourne, Australia, reinforcing its leadership in global bioinformatics, particularly in the Asia-Pacific region. This new…
Prolific Machines Appoints Christina Perry as CFO to Drive Biopharmaceutical Growth
Prolific Machines Appoints Christina Perry as CFO to Drive Biopharmaceutical Growth Prolific Machines, a leading biotechnology company specializing in using light to control biological processes, has announced the appointment of Christina Perry as its new Chief Financial Officer (CFO). In…
Pfizer’s TALZENNA® and XTANDI® Combo Enhances Survival in Metastatic Castration-Resistant Prostate Cancer
Pfizer’s TALZENNA® and XTANDI® Combo Enhances Survival in Metastatic Castration-Resistant Prostate Cancer Pfizer Inc. (NYSE: PFE) has announced promising results from the Phase 3 TALAPRO-2 study, which tested TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with…
GeneDx Launches 48-Hour Whole Genome Sequencing for Critical NICU and PICU Patients
GeneDx Launches 48-Hour Whole Genome Sequencing for Critical NICU and PICU Patients GeneDx (Nasdaq: WGS), a leader in genomic health insights, has unveiled ultraRapid Whole Genome Sequencing, providing quick, comprehensive genomic results for neonatal and pediatric patients in the NICU…
HealthStream’s CredentialStream® Achieves HITRUST r2 Certification for Top Healthcare Data Security
HealthStream’s CredentialStream® Achieves HITRUST r2 Certification for Top Healthcare Data Security HealthStream (Nasdaq: HSTM), a leading healthcare technology provider for workforce solutions, announced today that its SaaS-based CredentialStream application, along with CredentialStream Hub and Network by HealthStream, has received HITRUST…
Newleos Therapeutics Raises $93.5 Million in Oversubscribed Series A to Transform Neuropsychiatric Disorder Treatments
Newleos Therapeutics Raises $93.5 Million in Oversubscribed Series A to Transform Neuropsychiatric Disorder Treatments Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development, has successfully closed an oversubscribed $93.5 million Series…
CareDx to Present AlloHeme Data at 2025 Tandem Meetings on Early Relapse Detection
CareDx to Present AlloHeme Data at 2025 Tandem Meetings on Early Relapse Detection CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine focused on transplant patients and caregivers, today announced the presentation of new AlloHeme data at the 2025 Tandem…
CharmHealth Launches Marketplace and Innovation Hub for Healthcare Ecosystem
CharmHealth Launches Marketplace and Innovation Hub for Healthcare Ecosystem CharmHealth, a leader in healthcare technology solutions for providers, today introduced the CharmHealthHub, a premium marketplace designed to connect a wide range of healthcare stakeholders, including providers, practice groups, patients, entrepreneurs,…
Ensoma Gets Pediatric Disease and Orphan Drug Designations for EN-374 in Chronic Granulomatous Disease
Ensoma Gets Pediatric Disease and Orphan Drug Designations for EN-374 in Chronic Granulomatous Disease Ensoma, a genomic medicines company focused on developing one-time, in vivo treatments to precisely and durably engineer the hematopoietic system, announced that the U.S. Food and…